Table 1.
Cohort clinical and pathologic features
| Rapid Relapse | All patients n = 453 n (%) |
Rapid Relapse n = 110 n (%) |
Late Relapse n = 125 n (%) |
No Relapse n = 218 n (%) |
P |
|---|---|---|---|---|---|
| Age at diagnosis, by decade | 0.12 | ||||
| < 40 years | 75 (17) | 15 (14) | 27 (22) | 33 (15) | |
| 40 to 50 years | 117 (26) | 27 (24) | 28 (22) | 62 (29) | |
| 50 to 60 years | 124 (27) | 33 (30) | 25 (20) | 66 (30) | |
| > 60 years | 137 (30) | 35 (32) | 45 (36) | 57 (26) | |
| Grade at diagnosis | 0.86 | ||||
| I | 6 (2) | 2 (2) | 2 (2) | 2 (1) | |
| II | 54 (14) | 14 (15) | 17 (26) | 23 (13) | |
| III | 321 (84) | 75 (83) | 89 (82) | 157 (86) | |
| Stage at diagnosis | < 0.001 | ||||
| I | 73 (17) | 3 (3) | 18 (15) | 52 (25) | |
| II | 231 (54) | 43 (44) | 69 (56) | 119 (58) | |
| III | 123 (29) | 52 (53) | 35 (29) | 36 (27) | |
| Pam50 Subtype | 0.03 | ||||
| Basal | 354 (78) | 90 (82) | 89 (71) | 175 (80) | |
| Non-Basal | 99 (22) | 20 (18) | 36 (29) | 43 (20) | |
| TNBC Subtype | 0.02 | ||||
| Basal-like 1 | 103 (23) | 23 (21) | 26 (21) | 54 (25) | |
| Basal-like 2 | 40 (9) | 16 (15) | 11 (9) | 13 (6) | |
| Immunomodulatory | 91 (20) | 18 (16) | 20 (16) | 53 (24) | |
| Luminal androgen receptor | 49 (11) | 10 (9) | 20 (16) | 19 (9) | |
| Mesenchymal | 66 (14) | 19 (17) | 20 (16) | 27 (12) | |
| Mesenchymal stem-like | 24 (5) | 10 (9) | 3 (2) | 11 (5) | |
| Unselected | 80 (18) | 14 (13) | 25 (20) | 41 (19) | |
| Response to Neoadjuvant Chemo | < 0.001 | ||||
| Pathologic complete response | 29 (23) | 4 (7) | 1 (6) | 24 (49) | |
| Residual disease | 98 (77) | 57 (93) | 16 (94) | 25 (51) |